These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7383235)

  • 1. Impaired plasma phenytoin binding in uremia. Effect of in vitro acidification and anion-exchange resin.
    Depner TA; Stanfel LA; Jarrard EA; Gulyassy PF
    Nephron; 1980; 25(5):231-7. PubMed ID: 7383235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma protein binding in uremia: extraction and characterization of an inhibitor.
    Depner TA; Gulyassy PF
    Kidney Int; 1980 Jul; 18(1):86-94. PubMed ID: 7218662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid.
    Odar-Cederlöf I; Borga O
    Clin Pharmacol Ther; 1976 Jul; 20(1):36-47. PubMed ID: 1277724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction of drug binding defects in uremia in vitro by anion exchange resin treatment.
    Lichtenwalner DM; Suh B; Lorber B; Rudnick MR; Craig WA
    Biochem Pharmacol; 1982 Nov; 31(21):3483-7. PubMed ID: 7150368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A major inhibitor of phenytoin binding to serum protein in uremia.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 48(4):310-4. PubMed ID: 3362278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated free fosphenytoin concentrations in uremic sera: uremic toxins hippuric acid and indoxyl sulfate do not account for the impaired protein binding of fosphenytoin.
    Dasgupta A; Havlik D
    Ther Drug Monit; 1998 Dec; 20(6):658-62. PubMed ID: 9853983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure.
    Olsen GD; Bennett WM; Porter GA
    Clin Pharmacol Ther; 1975 Jun; 17(6):677-84. PubMed ID: 1095281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation of peptides from uremic plasma that inhibit phenytoin binding to normal plasma proteins.
    Kinniburgh DW; Boyd ND
    Clin Pharmacol Ther; 1981 Aug; 30(2):276-80. PubMed ID: 7249510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Role of uremic compounds.
    Dasgupta A; Abu-Alfa A
    Am J Clin Pathol; 1992 Jul; 98(1):19-25. PubMed ID: 1615921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation of inhibitors of ligand: albumin-binding from uremic body fluids and normal urine.
    Gulyassy PF; Bottini AT; Jarrard EA; Stanfel LA
    Kidney Int Suppl; 1983 Dec; 16():S238-42. PubMed ID: 6588258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temperature dependence of phenytoin-protein binding in serum: effects of uremia and hypoalbuminemia.
    Allison TB; Comstock TJ
    Ther Drug Monit; 1988; 10(4):376-81. PubMed ID: 3201522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenytoin-oxacillin interactions in normal and uremic sera.
    Dasgupta A; Sperelakis A; Mason A; Dean R
    Pharmacotherapy; 1997; 17(2):375-8. PubMed ID: 9085332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera.
    Dasgupta A; Timmerman TG
    Ther Drug Monit; 1996 Feb; 18(1):97-9. PubMed ID: 8848829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biophysical studies on the correction of uremic human serum albumin binding defects by in vitro charcoal adsorption treatment.
    Nikolaev V; Sarnatskaya V; von Appen K; Ivanov A; Rotellar E; Haspar M; Klinkmann H
    Artif Organs; 1996 Jan; 20(1):17-23. PubMed ID: 8645124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of salicylate binding to normal plasma by extracts of uremic fluids.
    Roman S; Gulyassy PF; Depner TA
    Am J Kidney Dis; 1984 Sep; 4(2):153-61. PubMed ID: 6475946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of total drug concentration on the free fraction in uremic sera.
    Tiula E; Neuvonen PJ
    Ther Drug Monit; 1986; 8(1):27-31. PubMed ID: 3961893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected suppression of free phenytoin concentration by salicylate in uremic sera due to the presence of inhibitors: MALDI mass spectrometric determination of molecular weight range of inhibitors.
    Biddle DA; Wells A; Dasgupta A
    Life Sci; 2000; 66(2):143-51. PubMed ID: 10666010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cortisol binding in uremic plasma. II. Decreased cortisol binding to albumin.
    Rosman PM; Benn R; Kay M; Wallace EZ
    Nephron; 1984; 37(4):229-31. PubMed ID: 6462312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma protein binding of phenytoin and warfarin in patients undergoing renal transplantation.
    Odar-Cederlof I
    Clin Pharmacokinet; 1977; 2(2):147-53. PubMed ID: 324689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.